Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

09_17 Bieker_2018 TVM Capital Life Science

2018 TVM Capital Life Science Autumn Conference

2018 TVM Capital Life Science Autumn Conference

Summary

Speakers

Kristina Bieker

Related Content

Recent Biologics Deals

Five Hot Trends in Life Sciences for 2025

Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2024-2025

Biocon Announces FDA Approval of Ustekinumab Biosimilar

Update on Pending Denosumab BPCIA Litigations

Preliminary Injunction Halts Corporate Transparency Act Enforcement: What You Need to Know

European Commission Approves Samsung Bioepis and Biogen’s Aflibercept Biosimilar

FDA approves CAR-T Cell Therapy for Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Goodwin Rare Disease Symposium 2025

Goodwin CLE Week 2025

Antag Therapeutics Closes €80 Million Series A Financing

AQEMIA Raises $38 Million

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Goodwin Advises Ampersand Capital Partners in Acquisition of Nektar Therapeutics’ PEG Supply Business and Manufacturing Facility

Destination Life Sciences M&A: Goodwin’s Q3 Momentum

Goodwin Advised Nuvig Therapeutics on $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator

Life Sciences